Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | LIPC | P11150 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6818404 | 0.95 | SRC (0.40) | CMKLR1ADORA1SRCABL1MAPK14 | |
| SCHEMBL6822483 | 0.94 | CMKLR1 (0.42) | CMKLR1ADORA1SRCABL1MCHR1 | |
| SCHEMBL6821500 | 0.92 | CMKLR1 (0.38) | CMKLR1ADORA1 | |
| SCHEMBL6822100 | 0.91 | ADORA1 (0.40) | CMKLR1ADORA1MCHR1KCNH2 | |
| SCHEMBL6822058 | 0.90 | ADORA1 (0.42) | CMKLR1ADORA1SRCABL1 | |
| SCHEMBL6821534 | 0.89 | ADORA1 (0.39) | CMKLR1ADORA1MCHR1 | |
| SCHEMBL6822546 | 0.89 | ADORA1 (0.41) | CMKLR1ADORA1SRCABL1 | |
| SCHEMBL6818702 | 0.88 | ADORA1 (0.46) | CMKLR1ADORA1 | |
| SCHEMBL6824716 | 0.88 | ADORA1 (0.40) | CMKLR1ADORA1 | |
| SCHEMBL6818520 | 0.88 | ADORA1 (0.40) | CMKLR1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | ADRB1, ADRA1D, ADRB3 | CMKLR1 4316/4885ADORA1 22/4885SRC 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.